You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 29, 2024

Claims for Patent: 8,980,272


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 8,980,272
Title:Antibody targeting osteoclast-associated protein
Abstract: The present invention relates to a method of detecting metabolic bone disorders using a gene expressed at a high level in osteoclasts, a method of screening for a compound effective for treatment and/or prevention of metabolic bone disorders, and a pharmaceutical composition for treatment and/or prevention of metabolic bone disorders. Specifically, the present invention relates to a method of detecting metabolic bone disorders using expression of the human DC-STAMP gene as an indicator, a pharmaceutical composition containing an antibody which is capable of specifically recognizing human DC-STAMP and suppressing formation of osteoclasts, and so forth.
Inventor(s): Nomiyama; Hisayuki (Kumamoto, JP), Kukita; Toshio (Fukuoka, JP), Hiruma; Yoshiharu (Tokyo, JP)
Assignee: Sankyo Company, Limited (Tokyo, JP)
Application Number:11/503,574
Patent Claims:1. A purified monoclonal antibody capable of binding to at least one human or murine dendritic cell specific transmembrane protein (DC-STAMP) selected from the group consisting of: a protein comprising the amino acid sequence of SEQ ID NO: 2, and a protein comprising the amino acid sequence of SEQ ID NO: 4, and suppressing formation of osteoclasts derived from murine bone marrow cells or suppressing formation of osteoclasts derived from human peripheral blood mononuclear cells, wherein the monoclonal antibody binds in the region of amino acid residues 330-343 of SEQ ID NO: 2 or in the region of amino acid residues 330-343 of SEQ ID NO: 4.

2. The purified antibody according to claim 1, wherein the antibody is humanized.

3. The purified antibody according to claim 1, wherein the antibody is a complete human antibody.

4. The purified antibody according to claim 1, wherein the antibody is an IgG antibody.

5. The purified antibody according to claim 1, wherein the antibody suppresses formation of osteoclasts derived from murine bone marrow cells at a concentration between 5 and 20 .mu.g/ml.

6. The purified antibody according to claim 1, wherein the antibody suppresses formation of osteoclasts derived from human peripheral blood mononuclear cells at a concentration between 2 and 6 .mu.g/ml.

7. A kit for detecting a metabolic bone disorder associated with an abnormal level of the DC-STAMP, comprising: (1) the purified antibody according to claim 1; and (2) a secondary antibody capable of binding to the antibody of (1).

8. A pharmaceutical composition for treatment of a metabolic bone disorder associated with an increased level of DC-STAMP, wherein the pharmaceutical composition comprises an antibody according to claim 1.

9. The pharmaceutical composition according to claim 8, wherein the metabolic bone disorder is osteoporosis, rheumatoid arthritis or cancerous hypercalcemia.

10. The pharmaceutical composition according to claim 8, wherein the metabolic bone disorder is osteoporosis.

11. The pharmaceutical composition according to claim 8, wherein the metabolic bone disorder is rheumatoid arthritis.

12. The pharmaceutical composition according to claim 8, wherein the metabolic bone disorder is cancerous hypercalcemia.

13. A pharmaceutical composition for treatment of a metabolic bone disorder associated with an increased level of DC-STAMP, wherein the pharmaceutical composition comprises an antibody according to claim 1 and at least one component selected from the group consisting of: bisphosphonates, activated vitamin D.sub.3, calcitonin and its derivatives, estradiol, SERMs (selective estrogen receptor modulators), ipriflavone, vitamin K.sub.2 (menatetrenone), calcium preparations, PTH (parathyroid hormone) preparations, non-steroidal anti-inflammatory agents, anti-TNF.alpha. (tumor necrosis factor .alpha.) antibodies, anti-PTHrP (parathyroid hormone-related protein) antibodies, IL-1 (interleukin 1) receptor antagonists, anti-RANKL (receptor activator of nuclear factor kappa-B ligand) antibodies and OCIF (osteoclastogenesis inhibitory factor).

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.